TB Research

Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021-2023.

Zhan Qiu Mao, Huilie Zheng, Hui Qiong Yang, Qian Zhong Liu, Yu Hong Xiong, Zhen Qiong Liu, Qi Long Zhang

BMC microbiology · 2026-01

Abstract

BACKGROUND: (NTM) pose diagnostic and therapeutic challenges in tuberculosis (TB)-endemic regions like Jiangxi Province, China, due to clinical and radiological similarities to TB. This study elucidates the molecular epidemiology of NTM in Jiangxi (2021–2023).

METHODS: A retrospective analysis of 20,724 clinical specimens from Jiangxi Chest Hospital was conducted using PCR-reverse blot hybridization assay (PCR-REBA) for NTM species identification. Inclusion required clinical/radiological suspicion of mycobacterial disease and specimens with sufficient volume (≥ 2 mL for liquid samples or ≥ 0.5 g for tissue). Statistical analyses determined prevalence, species distribution, and predictors.

RESULTS: Among 5,331 Mycobacterium-positive specimens, 333 (1.60%; 95% CI: 1.43&#x2013;1.77) were NTM. Males had significantly lower odds of infection than females (aOR 0.499,&#x2009;<&#x2009;0.001), with the highest prevalence observed in individuals aged&#x2009;&#x2265;&#x2009;65 years (2.64%) compared to the &#x2264;&#x2009;24 years reference group (aOR 12.922, 95% CI: 5.288&#x2013;31.578,&#x2009;<&#x2009;0.001). Dominant species were(MIN, 51.7%),(MAB, 30.9%), and(MAV, 9.3%). MIN and MAB predominated in pulmonary samples (97.9% of cases), while MAV showed significant extrapulmonary tropism (42.9% vs. 8.6% pulmonary,&#x2009;0.02). Detection rates fluctuated temporally (peak: 1.93% in 2021; trough: 1.20% in 2022;&#x2009;0.004), potentially influenced by the COVID-19 pandemic.

CONCLUSION: Jiangxi exhibits a distinct NTM profile with elevated MAB prevalence, emphasizing the need for species-level diagnosis to prevent misclassification as multidrug-resistant TB. Age, sex, and temporal trends emphasizing the critical need for species-level identification to facilitate early, targeted antimicrobial therapy and prevent the misclassification of NTM as multidrug-resistant TB.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12866-026-04732-2.